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REQUESTED COMMENT 
Tirone E. David, MD, Toronto, Ontario, Canada 
The concerns of Dr. Gallo and associates regarding out 
technique of reconstruction of the aortic root with pres- 
ervation of the aortic valve are valid. We also expressed 
concerns about it in our original article. 1 However, we 
have now preserved the aortic valve in more than 50 
patients with aortic root aneurysm and we have had only 
one late failure, which occurred in a teenager with 
Marfan's syndrome. 2 The aortic valve function has re- 
mained stable up to 5 years in the remaining patients. 
Patient selection is probably the single most important 
factor in the outcome of any valve repair. In patients with 
aortic root aneurysm the aortic valve should be repaired 
only when the leaflets are normal. In a normal eaflet the 
length of its base is approximately 1.5 times longer than 
the length of its free margin. Next, if the patient has severe 
aortic valve insufficiency, the cause of valve dysfunction 
must be determined and the appropriate surgical tech- 
nique used. When there is enlargement of both the 
aortoventricular junction and the sinotubular junction, an 
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aortic annuloplasty and resuspension of the leaflets in a 
Dacron fabric tube is necessary (we refer to this technique 
as "reimplantation of the aortic valve"). When only the 
sinotubular junction is enlarged, supraannular reconstruc- 
tion of the aortic root with or without reimplantation of 
the coronary arteries is done (we refer to this technique as 
"remodeling of the aortic root"). 2 
By using these techniques in carefully selected patients 
we have been able to provide excellent clinical results in 
51 of 53 patients operated on during the past 5 years. 
We remain carefully optimistic about these operative 
techniques. Observations uch as those of Gallo and 
colleagues are important as surgeons introduce new op- 
erative techniques and they stress the necessity of continu- 
ing follow-up of these patients. 
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LIDOFLAZINE AND MYOCARDIAL PROTECTION 
B. Akpinar, MD,* H. Vanerman, MD, and F. Wellens, MD, Aalst, Belgium 
Lately interest in the myocardial protective ffects of 
lidofiazine (Janssen Research Foundation, Beerse, Bel- 
gium) has been renewed. Although many clinical and 
experimental studies on this drug have been conducted, 
the mechanism of its cardioprotective effect has not been 
completely established. Selective calcium entry blocking 
activity of the drug was not demonstrated, but the latest 
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studies focus more on the nucleoside transport inhibitory 
effect of lidoflazine. 1'2 
For more than a decade, we have been using lidoflazine 
pretreatment, moderate hypothermia, nd a single period 
of crossclamping for coronary artery operations, with 
excellent results. We wanted to make a comparative study 
to evaluate the myocardial protective ffect of lidoflazine 
using hemodynamic, biochemical, and clinical parameters. 
Fifty patients, 25 in each group, were selected according 
to their age, sex, and left ventricular ejection fraction. 
Patients older than 70 years of age, patients with com- 
bined procedures or reoperations, and patients with an 
impending myocardial infarction were excluded from the 
study. Left ventricular ejection fraction less than 30% was 
also an exclusion criteria. Data on both groups A and B 
are shown in Table I. 
In group A, in which lidofiazine and a single crossclamp 
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Table I. Comparison of the two groups according to 
age, crossclamp times, and number of distal 
anastomoses 
Group A Group B 
Age (yr) 62 + 4 63 -+ 3 
Crossclamp time (min) 38 + 3 40 _+ 2 
No. of distal anastomoses 3.5 _+ 0.5 3.4 + 0.4 
technique were used, the patients received a 1 mg/kg dose 
of lidoflazine after the sternum was open. The heart was 
fibrillated and the crossclamp was applied. All the distal 
anastomoses were then performed uring one period of 
crossclamping. 
In group B, after the aorta was crossclamped, 1 L of 
cold crystalloid cardioplegic solution (a St. Thomas' Hos- 
pital solution; Plegisol, Abbott Laboratories, Chicago, Ill.) 
was administered antegradely. Additional doses of crys- 
talloid cardioplegic solution were given every 20 minutes. 
Topical cooling with cold water was also used. 
In both groups, the patients were cooled to 28 ° C and 
proximal anastomoses were pefformed in a similar fashion. 
Arterial-coronary sinus differences in lactate and inor- 
ganic phosphate were determined in all patients before 
the aorta was crossclamped and in the first, fifth, and 
twentieth minutes after the aortic clamp had been re- 
moved. The maximum washout occurred immediately 
after the release of the clamp and declined gradually in 
both groups; however, we observed a greater washout of 
lactate and inorganic phosphate in group A than in group 
B (p < 0.05). (Differences between related values were 
tested for statistical significance by the Wilcoxon test. 
Two-tailed probabilities as small as 0.05 were regarded as 
significant.) This change in group A reached the statisti- 
cally significant level (p < 0.05, Wilcoxon test). 
Creatine kinase MB levels measured 2 hours after the 
operation were higher in group A. However, a decline in 
enzyme levels was noted in both groups at the end of 24 
hours, and there was no statistically significant difference 
between the two groups at that time (Table II). 
In all these patients the electrocardiographic tra ings 
were not different from the preoperative tracings. No 
significant difference was found between the two groups in 
terms of blood pressure, heart rate, pulmonary capillary 
wedge pressure, and cardiac index 5, 10, and 15 minutes 
after the termination of cardiopulmonary b pass. During 
the reperfusion period, rhythm disturbances such as atrial 
fibrillation and atrioventricular conduction disturbances 
were observed in five patients in group A but in no 
patients in group B. 
The clinical outcome was excellent in all patients. There 
was no need for inotropic support after cardiopulmonary 
bypass, and no postoperative myocardial infarctions were 
Table II. Decline in CK-MB values at the end of 
24 hours 
CK-MB (mol/L )
2 hr 24 hr 
postop, postop. 
Group A 28 + 5 7 _+ 3 
(n = 25) 
Group B 21 + 4 5 -+ 2 
(n = 25) 
Data are mean values -+ standard eviation. CK Creatine kinase. 
detected. One limitation of this study is the fact that the 
patients in groups A and B were operated on by two 
different surgeons, and another limitation is the relatively 
short crossclamp times. However, in out clinical experi- 
ence we have had longer periods of ischemia with the 
method used in group A without any problems. 
Many studies have been published on the myocardial 
protective ffects of lidoflazine, and some groups have 
reported excellent results in coronary artery operations 
using pretreatment with lidoflazine and intermittent aortic 
crossclamping. 3-5To our knowledge, pretreatment with 
lidoflazine and single crossclamping has not been previ- 
ously reported. Although the biochemical markers in our 
series suggested more reversible ischemic damage in 
group A, our clinical experience suggests that this is a safe 
method, because it offers excellent early and late results. 
Lidoflazine may have a wider use in myocardial protection 
in the future. 
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